Antibody-drug conjugates are big business, with the market leader, AstraZeneca PLC and Daiichi Sankyo Co., Ltd.’s Enhertu (trastuzumab deruxtecan), forecast to make more than $14bn in 2030 according to Evaluate Pharma.
This has inspired many followers, many of which are working on optimizing either the chemotherapy payload or linker technology used by ADCs
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?